GlassScriptPhysician profile
Fe V Pancito
NPI 1922004001
$18,132.22
in general payments reported to CMS, 2019-2025
61 companies · $3,676 in 2025
The $3,676 reported for 2025 was more than what 93% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,073 · 2020: $1,087 · 2021: $1,553 · 2022: $3,139 · 2023: $3,625 · 2024: $3,980 · 2025: $3,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,280.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,845.59 | 2019-2025 | Enhertu, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $1,146.24 | 2021-2025 | Reblozyl, Opdivo, Abecma |
| Janssen Biotech, INC. | $1,026.66 | 2020-2025 | Carvykti, Rybrevant, Darzalex |
| Regeneron Healthcare Solutions, INC. | $881.50 | 2021-2025 | Libtayo |
| Incyte Corporation | $850.76 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $685.53 | 2019-2024 | Lunsumio, Alecensa, Tecentriq |
| Daiichi Sankyo INC. | $649.70 | 2020-2025 | Enhertu |
| Seagen INC. | $635.10 | 2019-2023 | Tukysa, Adcetris |
| Abbvie INC. | $548.55 | 2019-2025 | |
| Astellas Pharma US INC | $547.40 | 2019-2025 | Xtandi, Vyloy |
| Amgen INC. | $488.20 | 2022-2025 | Blincyto, Kyprolis, Lumakras |
| Glaxosmithkline, LLC. | $486.90 | 2021-2025 | Zejula, Ojjaara, Jemperli |
| Merck Sharp & Dohme LLC | $451.43 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $413.73 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $387.88 | 2021-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fe Pancito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.